IL17C
Overview[edit | edit source]
IL17B is a member of the interleukin 17 (IL-17) cytokine family, which plays a crucial role in the immune system by mediating pro-inflammatory responses. The IL-17 family consists of six members, IL-17A through IL-17F, with IL17B being one of the less studied but increasingly recognized for its role in various physiological and pathological processes.
Structure and Function[edit | edit source]
IL17B is a homodimeric glycoprotein that is primarily expressed in the nervous system and peripheral tissues. It binds to the IL-17RB receptor, which is distinct from the receptor for IL-17A, the most well-known member of the IL-17 family. Upon binding to its receptor, IL17B activates downstream signaling pathways that lead to the production of pro-inflammatory cytokines and chemokines.
Role in Inflammation[edit | edit source]
IL17B has been implicated in the regulation of inflammatory responses. It is known to induce the expression of TNF-alpha, IL-1beta, and other inflammatory mediators in various cell types. This makes IL17B a potential target for therapeutic intervention in inflammatory diseases.
Role in Disease[edit | edit source]
Research has shown that IL17B may play a role in several diseases, including:
- Cancer: IL17B expression has been associated with tumor progression and poor prognosis in certain cancers, such as breast cancer and pancreatic cancer. It may promote tumor growth by enhancing angiogenesis and suppressing anti-tumor immune responses.
- Autoimmune Diseases: IL17B may contribute to the pathogenesis of autoimmune diseases by promoting inflammation and tissue damage.
- Neurological Disorders: Given its expression in the nervous system, IL17B may be involved in neuroinflammatory conditions, although more research is needed to fully understand its role.
Research and Therapeutic Potential[edit | edit source]
The study of IL17B is ongoing, with researchers exploring its potential as a biomarker for disease and as a target for new therapies. Inhibitors of IL17B or its receptor could potentially be developed to treat conditions where IL17B is implicated.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
